Drug therapy may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases, according to a new study by Mayo Clinic researchers. The study was posted in March on Gastroenterology, the online journal of the American Gastroenterological Association. Print publication is scheduled for July.
While therapies have been available to treat some forms of liver disease, including hepatitis C and autoimmune hepatitis, options have been more limited for treating portal hypertension, a condition where there is an increase in pressure within the portal vein that carries blood from abdominal organs to the liver. Portal hypertension is associated with cirrhosis and other chronic liver diseases.
According to the study, the drug sivelestat may effectively lower portal hypertension, improving symptoms and outcomes for those patients. The study results were obtained from mouse models but have since been confirmed in liver samples from humans, according to Vijay Shah, M.D., a Mayo Clinic gastroenterologist and senior author.
“This was an exciting confirmation of our findings and their applicability to human disease,” Dr. Shah says. “Sivelestat has been safely used in humans with acute lung injury and bronchopulmonary dysplasia. This suggests that sivelestat and similar drugs constitute a potential means to decrease portal hypertension in patients with chronic liver disease.”
The Mayo study showed that deposits of fibrin — microvascular blood clots — contributed to portal hypertension, and inflammatory cells known as neutrophils contributed to the formation of fibrin. By inhibiting neutrophil function with sivelestat, they were able to decrease portal hypertension.
“Neutrophils had not previously been identified as significant drivers of portal hypertension,” says Moira Hilscher, M.D., the paper’s first author. Results were verified in two different models of chronic liver disease.
“The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces,” says Dr. Hilscher. “Given the increasing prevalence of advanced liver disease due to alcohol and obesity, this is clearly an unmet need.”
The Latest on: Liver diseases
via Google News
The Latest on: Liver diseases
- Global Liver Cirrhosis Treatment Market To Ascend Pervasively By 2025, Registering more than US$ 1349.92 Million Revenue; Asserts MRFRon January 12, 2021 at 11:27 am
Market Highlights According to MRFR analysis, the global liver cirrhosis treatment market is expected to register a CAGR ...
- Pediatric Liver Cancer Cases Have Increased Over Last 30 Yearson January 12, 2021 at 11:12 am
Over the last 30 years, cases of childhood liver cancer have increased in the United States, Australia and a Canadian province.
- Discovery of a new approach to inhibiting a highly treatment-refractory liver canceron January 12, 2021 at 9:06 am
Reprogramming the rich connective tissue microenvironment of a liver cancer known as intrahepatic cholangiocarcinoma (ICC) inhibits its progression and resistance to standard chemotherapy in animal ...
- Making a Case for Going Beyond the Liver to Include Muscles for NAFLD: A Systematic Review Publishedon January 12, 2021 at 7:04 am
A perspective review article titled "Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis" was recently published ...
- University Hospital Center for Advanced Liver Diseases and Transplantation has best one-year survival rate nationwideon January 11, 2021 at 12:38 pm
The liver transplant center opened in 1989 as the first in the state and is now one of 61 such centers nationally. Physicians at the center have performed more than 1,500 liver transplant surgeries, ...
- University Hospital’s Liver Transplant Program Ranks No. 1 in United Stateson January 11, 2021 at 11:59 am
NEWARK, NJ — University Hospital, New Jersey’s state-owned public hospital, received the top designation for its liver transplant program on Monday, distinguishing it as the leader in ...
- Toddler gets liver transplant, survives COVID-19 diagnosis before first birthdayon January 11, 2021 at 11:23 am
Kasen Donerlson was just months old when he was diagnosed with a rare liver disease. Kasen has biliary atresia which causes blockages between his liver and gallbladder. Johns Hopkins University says ...
- Study highlights racial disparities in liver transplantation listingon January 11, 2021 at 9:02 am
Hispanic white patients get placed on liver transplant waitlists at disproportionately higher rates than non-Hispanic Black patients.
- Non-Hispanic Black patients are disproportionately left off liver transplant waitlistson January 11, 2021 at 8:30 am
Hispanic white patients get placed on liver transplant waitlists at disproportionately higher rates than non-Hispanic Black patients. However, researchers went a step further as they identified key ...
- Baby with liver disease survives COVID-19on January 11, 2021 at 5:20 am
As she plans to make it all work, she's also ready to celebrate his very first birthday on Jan. 14. A birthday he was not guaranteed with a mom now hopeful for many more. Other family members also ...
via Bing News